Amphastar Pharmaceuticals Aktie
WKN DE: A11664 / ISIN: US03209R1032
29.12.2020 12:11:48
|
Amphastar Pharma: FDA Approves Glucagon For Injection Emergency Kit, 1 Mg - Quick Facts
(RTTNews) - Amphastar Pharmaceuticals, Inc. (AMPH) said the FDA has approved its Abbreviated New Drug Application for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated for the treatment of severe hypoglycemia and is also used as a diagnostic aid. The company plans to launch Glucagon for Injection Emergency Kit, which it previously referred to as AMP-001, within two months.
Amphastar's CEO, Jack Zhang, stated: "This approval is yet another milestone for the Company and marks the first-ever FDA approval of a generic version of rDNA Glucagon."

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Amphastar Pharmaceuticals Incmehr Nachrichten
26.02.25 |
Ausblick: Amphastar Pharmaceuticals präsentiert Quartalsergebnisse (finanzen.net) | |
05.11.24 |
Ausblick: Amphastar Pharmaceuticals informiert über die jüngsten Quartalsergebnisse (finanzen.net) |
Analysen zu Amphastar Pharmaceuticals Incmehr Analysen
Aktien in diesem Artikel
Amphastar Pharmaceuticals Inc | 25,82 | 0,19% |
|